drugset / Trial / NCT05252091
An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in non-small cell lung cancer
Timeline
- Start
- 2022-02-20
- Primary completion
- 2022-08-20
- Completion
- 2022-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RAFUTROMBOPAG | Other / unclassified | 5 mg | Oral |